Mednet Logo
HomeQuestion

After the results of RTOG 0232, would you be comfortable treating unfavorable intermediate risk prostate cancer with brachytherapy monotherapy?

2
4 Answers
Mednet Member
Mednet Member
Radiation Oncology · Virginia Commonwealth University Medical Center

I would not necessarily be comfortable treating every unfavorable intermediate risk (UIR) patient with LDR brachytherapy alone (nor with HDR brachy alone). My reason for this is that 0232 only included about 50 patients in each arm with Grade Group 3 tumors, and no information is available about per...

Register or Sign In to see full answer

Mednet Member
Mednet Member
Radiation Oncology · Varian Medical Systems/Allegheny health network

We have moved to brachy alone if meets the above criteria as similar outcome and less morbidity.

Register or Sign In to see full answer

Mednet Member
Mednet Member
Radiation Oncology · GammaWest Cancer Services

I concur with the excellent comments by Dr. @Dr. First Last and add the following:

The RTOG 0232 trial included patients with cT1c-T2bN0M0 disease with a Gleason score of 2-6 and PSA of 10-20 or with a Gleason score of 7 with a PSA <10. The majority of patients were T1, Gleason score 7, with PSA <10....

Register or Sign In to see full answer

Mednet Member
Mednet Member
Radiation Oncology · Allegheny Health Network

I typically get a PSMA PET in these patients and urge them to consider short course ADT along with either LDR or HDR with a preference for HDR.

Register or Sign In to see full answer

After the results of RTOG 0232, would you be comfortable treating unfavorable intermediate risk prostate cancer with brachytherapy monotherapy? | Mednet